Filippo Crivelli

Filippo Crivelli

Auto-generated profile, based on publicly available information

Filippo Crivelli

Oncology-Hematology Unit, ASST Valle Olona, Busto Arsizio, Italy. 6

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
RSRoberta Sulsenti
Roberta Sulsenti
GSGiuseppina Beatrice. Scialpi
Giuseppina Beatrice. Scialpi
Barbara FrossiBarbara Frossi
Barbara Frossi
LBLaura Botti
Laura Botti
RFRenata Ferri
Renata Ferri
EJElena Jachetti
Elena Jachetti
Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer that emerges as tumors become resistant to hormone therapies or, rarely, arises de novo in treatment-naïve patients. The urgent need for effective therapies against NEPC is hampered by the limited knowledge of the biology governing this lethal disease. Based on our prior observations in the transgenic adenocarcinoma of the mouse prostate (TRAMP) spontaneous prostate cancer model, in which the genetic depletion of either mast cells (MC) or the matricellular protein osteopontin (OPN) increases NEPC frequency, we tested the hypothesis that MCs can restrain NEPC through OPN production, using in vitro co-cultures between murine or human tumor cell lines and MCs, and in vivo experiments. We unveiled a role for the intracellular isoform of OPN, so far neglected compared with the secreted isoform. Mechanistically, we unraveled that the intracellular isoform of OPN promotes TNFα production in MCs via the TLR2/TLR4-MyD88 axis, specifically triggered by the encounter with NEPC cells. We found that MC-derived TNFα, in turn, hampered the growth of NEPC. We then identified the protein syndecan-1 (SDC1) as the NEPC-specific TLR2/TLR4 ligand that triggered this pathway. Interrogating published single-cell RNA-sequencing data, we validated this mechanism in a different mouse model. Translational relevance of the results was provided by in silico analyses of available human NEPC datasets and by immunofluorescence on patient-derived adenocarcinoma and NEPC lesions. Overall, our results show that MCs actively inhibit NEPC, paving the way for innovative MC-based therapies for this fatal tumor. We also highlight SDC1 as a potential biomarker for incipient NEPC.

1 May 2019 in La Rivista Italiana della Medicina di Laboratorio
Verified
Journal Article
Closed access
VMValentino Miconi
Valentino Miconi
Bruno BRANDOBruno BRANDO
Bruno BRANDO
PCPierangelo Clerici
Pierangelo Clerici
FCFilippo Crivelli
Filippo Crivelli
FCFrancesco Curcio
Francesco Curcio
ACAnna Maria Cenci
Anna Maria Cenci

3 September 2024
Verified
Other
Open access
RSRoberta Sulsenti
Roberta Sulsenti
GSGiuseppina B. Scialpi
Giuseppina B. Scialpi
Barbara FrossiBarbara Frossi
Barbara Frossi
LBLaura Botti
Laura Botti
RFRenata Ferri
Renata Ferri
EJElena Jachetti
Elena Jachetti
Supplementary table 2 - list of siRNA and Taqman assays used in the study

3 September 2024
Verified
Other
Open access
PDF file
RSRoberta Sulsenti
Roberta Sulsenti
GSGiuseppina B. Scialpi
Giuseppina B. Scialpi
Barbara FrossiBarbara Frossi
Barbara Frossi
LBLaura Botti
Laura Botti
RFRenata Ferri
Renata Ferri
EJElena Jachetti
Elena Jachetti
Supplementary Figure S3. Toluidine blue for detection of MCs in mice. A. MC count reported as number of MCs/tumor area (cm2) in tumor samples from TRAMP mice with prostate intraepithelial neoplasia or adenocarcinoma (PIN/ADENO, n= 12), or TRAMP mice with NEPC (n= 3), as well as in prostatectomies from untreated patients with Gleason Score 7 (n= 10), Gleason Score 8 (n=10), or showing evidence of NEPC (n= 4). The histogram depict mean ± SD of biological replicates (represented by dots). B. Upper panels: representative images of toluidine blue staining in TRAMP, KitWsh-TRAMP, and OPN-/-TRAMP mice, or in KitWsh-TRAMP mice reconstituted with WT, OPN-/- or TNFa-/- MCs. Lower panels: representative images of toluidine blue staining in a prostate of a patient with adenocarcinoma. Scale bars indicate magnifications.

3 September 2024
Verified
Other
Open access
RSRoberta Sulsenti
Roberta Sulsenti
GSGiuseppina B. Scialpi
Giuseppina B. Scialpi
Barbara FrossiBarbara Frossi
Barbara Frossi
LBLaura Botti
Laura Botti
RFRenata Ferri
Renata Ferri
EJElena Jachetti
Elena Jachetti
Supplementary table 3 - List of putative NEPC-specific surface TLR ligands

3 September 2024
Verified
Other
Open access
RSRoberta Sulsenti
Roberta Sulsenti
GSGiuseppina B. Scialpi
Giuseppina B. Scialpi
Barbara FrossiBarbara Frossi
Barbara Frossi
LBLaura Botti
Laura Botti
RFRenata Ferri
Renata Ferri
EJElena Jachetti
Elena Jachetti
Supplementary table 2 - list of siRNA and Taqman assays used in the study